Avalon GloboCare Forms Strategic Partnership with Major Biomedical Enterprise Da An Gene

FREEHOLD, NJ--(Marketwired - January 30, 2018) - Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that the Company has formed a strategic partnership with Da An Gene Co., Ltd, a major biomedical company publicly listed on the Shenzhen Stock Exchange (002030.SZ), to further optimize Avalon's exosome-based technology, clinical development, as well as product commercialization.

Da An Gene is an eminent biomedical enterprise which consists of a number of research institutes in China, including the Medical Biotechnology Research Center under the Ministry of Health, the Clinical Medical Molecular Diagnostic Engineering Laboratory of Guangdong Province and Guangzhou Antibody Engineering Technology Research Center. Da An Gene has independent intellectual property rights in their proprietary core technology platform of fluorescent quantitative polymerase chain reaction (FQ-PCR) diagnostic reagents - the first of its kind in the world. The Company is a domestic leader in China for product commercialization in the molecular diagnostics sector, as well as innovative product research, development and application.

In this strategic partnership, Avalon and Da An Gene will synergize resources to accelerate exosome-based in vitro diagnostic product development and commercialization. Da An Gene has agreed to prioritize the utility and purchase of technologies and products by Avalon and its subsidiary GenExosome Technologies. In addition, taking advantage of the academic excellence in translational research at Da An/Sun Yat-sen University School of Medicine and affiliated hospitals, this partnership will promote and foster biomedical innovation as well as clinical advancement in the fields of molecular pathology and regenerative medicine.

"This strategic partnership with Da An Gene will significantly accelerate our product development and commercialization in the fields of liquid biopsy and in vitro diagnostics," said David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare, as well as co-CEO of its subsidiary GenExosome Technologies Inc. "The specialty of Da An's genomic sequencing and profiling platform, in combination with our proprietary exosome isolation system and clinical expertise in regenerative medicine, will further establish Avalon's leading role in precision and regenerative medicine," added Dr. Jin.

About Da An Gene Co., Ltd
Da An Gene, part of Sun Yat-sen University School of Medicine located in Guangzhou, China, is a leading biomedical company focusing on molecular diagnostic technology, production and sales of clinical test reagents and instruments, as well as clinical testing services of national independent medical labs. The Company, which was listed on the Shenzhen Stock Exchange in August 2004 (SZ 002030), has become the first listed company among the university-run enterprises in Guangdong Province.

About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.